SCHEMBL9746172

SCHEMBL9746172

CCCCC(=O)CCCC[C]=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
MAPT P10636 1/20 0.50
PTPN7 P35236 3/20 0.45
HMGCR P04035 3/20 0.45
CES2 O00748 5/20 0.44
CES1 P23141 5/20 0.44
ALDH1A1 P00352 3/20 0.41
AKR1B1 P15121 1/20 0.41
TP53 P04637 1/20 0.41
HAO1 Q9UJM8 1/20 0.41
PPARG P37231 4/20 0.39
PPARD Q03181 4/20 0.39
PPARA Q07869 4/20 0.39
TSHR P16473 3/20 0.39
GPR84 Q9NQS5 3/20 0.39
HDAC11 Q96DB2 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
SLC22A6 Q4U2R8 1/20 0.39
SLC22A8 Q8TCC7 1/20 0.39
TLR2 O60603 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10607844 0.98 KMT2A (0.54) KMT2AMAPTPTPN7HMGCRCES2
SCHEMBL2452930 0.93 KMT2A (0.59) KMT2AMAPTPTPN7HMGCRCES2
SCHEMBL9421864 0.93 KMT2A (0.59) KMT2AMAPTPTPN7HMGCRCES2
SCHEMBL27371777 0.93 KMT2A (0.59) KMT2AMAPTPTPN7HMGCRCES2
SCHEMBL1019921 0.93 KMT2A (0.59) KMT2AMAPTPTPN7HMGCRCES2
SCHEMBL19547103 0.93 MAPT (0.46) KMT2AMAPTPTPN7HMGCRCES2
SCHEMBL8496725 0.91 KMT2A (0.45) KMT2AMAPTPTPN7HMGCRCES2
SCHEMBL8060807 0.89 KMT2A (0.48) KMT2AMAPTPTPN7HMGCRCES2
SCHEMBL27703598 0.86 KMT2A (0.56) KMT2AMAPTPTPN7HMGCRCES2
SCHEMBL11577506 0.84 KMT2A (0.59) KMT2AMAPTPTPN7HMGCRCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0162764-A1 Composition and method for enhancing absorption of drugs from gastrointestinal tract using acylcarnitines MERCK & CO. INC. (US) 1985-11-27 EP claimed
EP-0214898-B1 CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES MERCK & CO. INC. (US) 1992-03-11 EP disclosed
US-4973579-A VIRICIDES MERCK & CO., INC. (US) 1990-11-27 US disclosed
US-4963556-A ANTIVIRAL AGENTS MERCK & CO., INC. (US) 1990-10-16 US disclosed
EP-0162764-B1 COMPOSITION AND METHOD FOR ENHANCING ABSORPTION OF DRUGS FROM GASTROINTESTINAL TRACT USING ACYLCARNITINES MERCK & CO. INC. (US) 1989-08-09 EP disclosed
US-4835138-A Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities MERCK & CO., INC. (US) 1989-05-30 US disclosed
US-4822773-A Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts MERCK & CO., INC. (US) 1989-04-18 US disclosed
US-4729989-A Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts MERCK & CO., INC. (US) 1988-03-08 US disclosed
US-4692441-A B-LACTAM ANTIBIOTICS MERCK & CO., INC. (US) 1987-09-08 US disclosed
EP-0214898-A2 Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities MERCK & CO. INC. (US) 1987-03-18 EP disclosed
EP-0206947-A2 Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption MERCK & CO. INC. (US) 1986-12-30 EP disclosed
EP-0162764-A1 Composition and method for enhancing absorption of drugs from gastrointestinal tract using acylcarnitines MERCK & CO. INC. (US) 1985-11-27 EP disclosed
US-4537772-A Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines MERCK & CO., INC. (US) 1985-08-27 US disclosed